UCB Invests $2B in Georgia Biologics Plant

0:00Belgian drug maker UCB plans to pour $2 billion into a new manufacturing plant just outside Atlanta in Gwinnit County, Georgia. The facility will produce biologics to ramp up supply for treatments targeting neurological and autoimmune conditions. This move builds on UCB's shift from older anti-histamines like Zyrtec and Zyzao to newer blockbusters such as Vimzilex, which fights psoriasis and arthritis. The company sees steady demand growth and wants reliable access for patients. Local leaders are excited about the site in a budding research part, close to Georgia Tech and the University of Georgia, both pushing biomedical. Innovation. UCB's US headquarters already sits in nearby Smerna, strengthening Atlanta's biotech draw. Construction and design will span 6 to 7 years, with Gwinnit County offering $174 million in incentives like tax, breaks, and infrastructure upgrades. State perks could add more, supporting hundreds of jobs averaging over $72,000 a year.

1:04As this project takes shape, it signals more investment flowing into Georgia's life sciences hub, promising jobs and cutting edge meds for years. Ahead, that's the story for today. Canada News Today, Driven by AI, I'm Corey with The Story.